Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2002 + SHR-1316 in Advanced Malignant Tumors
NCT05082545Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHR-2002 in cancer (3 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Adverse events and Number of participants experiencing Dose-Limiting Toxicities up to 42 days. Started Nov 2021; status: completed.
02
Drugs
SHR-2002
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05082545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082545.